Equities research analysts at Evercore ISI began coverage on shares of Hinge Health (NYSE:HNGE - Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The brokerage set an "outperform" rating and a $50.00 price target on the stock. Evercore ISI's target price would suggest a potential upside of 43.84% from the company's previous close.
A number of other research firms have also commented on HNGE. KeyCorp initiated coverage on Hinge Health in a report on Monday. They issued an "overweight" rating and a $45.00 price target for the company. Wall Street Zen raised shares of Hinge Health to a "hold" rating in a research note on Monday, June 2nd. Needham & Company LLC assumed coverage on shares of Hinge Health in a research note on Monday. They issued a "buy" rating and a $47.00 target price on the stock. Canaccord Genuity Group started coverage on shares of Hinge Health in a research report on Monday. They set a "buy" rating and a $52.00 price target for the company. Finally, Bank of America assumed coverage on shares of Hinge Health in a report on Monday. They issued a "buy" rating and a $42.00 price target on the stock. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Hinge Health presently has a consensus rating of "Moderate Buy" and an average target price of $46.00.
Check Out Our Latest Research Report on HNGE
Hinge Health Price Performance
Shares of NYSE:HNGE opened at $34.76 on Monday. Hinge Health has a twelve month low of $33.42 and a twelve month high of $43.80.
About Hinge Health
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
